CAMBRIDGE, Mass., Jan. 5, 2015 (GLOBE NEWSWIRE) -- SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced that Jeffrey Jonas, M.D., chief executive officer, is scheduled to present a company overview and update at the 33rd Annual J.P. Morgan Healthcare Conference at 11:30 a.m. PT on Monday, January 12, 2015 at the Westin St. Francis Hotel in San Francisco.
A live webcast of the presentation can be accessed by visiting the investors section of SAGE's website at investor.sagerx.com. A replay of the webcast will also be archived on SAGE's website following the presentation.
About SAGE Therapeutics
SAGE Therapeutics (Nasdaq:SAGE) is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare central nervous system, or CNS disorders. SAGE's lead program, SAGE-547, is in clinical development for super-refractory status epilepticus, or SRSE, and is the first of several compounds the company is developing in its portfolio of potential seizure medicines. SAGE's proprietary chemistry platform has generated multiple new compounds that target GABAA and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders. For more information, please visit www.sagerx.com.
CONTACT: Media Contact:
Dan Budwick, Pure Communicationsdan@purecommunicationsinc.com
973-271-6085
Investor Contact:
Monique Allaire Lyons, Pure Communicationsmonique@purecommunicationsinc.com
781-631-0759
Source:
SAGE Therapeutics
News Provided by Acquire Media
